Cargando…

Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo

Silver nanoparticles (AgNPs) show promise for treatment of aggressive cancers including triple‐negative breast cancer (TNBC) in preclinical cancer models. For clinical development of AgNP‐based therapeutics, it will be necessary to clearly define the specific physicochemical features of the nanopart...

Descripción completa

Detalles Bibliográficos
Autores principales: Swanner, Jessica, Fahrenholtz, Cale D., Tenvooren, Iliana, Bernish, Brian W., Sears, James J., Hooker, Allison, Furdui, Cristina M., Alli, Elizabeth, Li, Wencheng, Donati, George L., Cook, Katherine L., Vidi, Pierre‐Alexandre, Singh, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996381/
https://www.ncbi.nlm.nih.gov/pubmed/32123812
http://dx.doi.org/10.1096/fba.2019-00021
_version_ 1783493512973516800
author Swanner, Jessica
Fahrenholtz, Cale D.
Tenvooren, Iliana
Bernish, Brian W.
Sears, James J.
Hooker, Allison
Furdui, Cristina M.
Alli, Elizabeth
Li, Wencheng
Donati, George L.
Cook, Katherine L.
Vidi, Pierre‐Alexandre
Singh, Ravi
author_facet Swanner, Jessica
Fahrenholtz, Cale D.
Tenvooren, Iliana
Bernish, Brian W.
Sears, James J.
Hooker, Allison
Furdui, Cristina M.
Alli, Elizabeth
Li, Wencheng
Donati, George L.
Cook, Katherine L.
Vidi, Pierre‐Alexandre
Singh, Ravi
author_sort Swanner, Jessica
collection PubMed
description Silver nanoparticles (AgNPs) show promise for treatment of aggressive cancers including triple‐negative breast cancer (TNBC) in preclinical cancer models. For clinical development of AgNP‐based therapeutics, it will be necessary to clearly define the specific physicochemical features of the nanoparticles that will be used, and to tie these properties to biological outcomes. To fill this knowledge gap, we performed thorough structure/function, mechanistic, safety, and efficacy studies to assess the potential for AgNPs to treat TNBC. We establish that AgNPs, regardless of size, shape, or stabilizing agent, are highly cytotoxic to TNBC cells at doses that are not cytotoxic to non‐malignant breast epithelial cells. In contrast, TNBC cells and non‐malignant breast epithelial cells are similarly sensitive to exposure to silver cation (Ag(+)), indicating that the nanoparticle formulation is essential for the TNBC‐specific cytotoxicity. Mechanistically, AgNPs are internalized by both TNBC and non‐malignant breast cells, but are rapidly degraded only in TNBC cells. Exposure to AgNPs depletes cellular antioxidants and causes endoplasmic reticulum stress in TNBC cells without causing similar damage in non‐malignant breast epithelial cells. AgNPs also cause extensive DNA damage in 3D TNBC tumor nodules in vitro, but do not disrupt the normal architecture of breast acini in 3D cell culture, nor cause DNA damage or induce apoptosis in these structures. Lastly, we show that systemically administered AgNPs are effective at non‐toxic doses for reducing the growth of TNBC tumor xenografts in mice. This work provides a rationale for development of AgNPs as a safe and specific TNBC treatment.
format Online
Article
Text
id pubmed-6996381
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69963812020-03-02 Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo Swanner, Jessica Fahrenholtz, Cale D. Tenvooren, Iliana Bernish, Brian W. Sears, James J. Hooker, Allison Furdui, Cristina M. Alli, Elizabeth Li, Wencheng Donati, George L. Cook, Katherine L. Vidi, Pierre‐Alexandre Singh, Ravi FASEB Bioadv Research Articles Silver nanoparticles (AgNPs) show promise for treatment of aggressive cancers including triple‐negative breast cancer (TNBC) in preclinical cancer models. For clinical development of AgNP‐based therapeutics, it will be necessary to clearly define the specific physicochemical features of the nanoparticles that will be used, and to tie these properties to biological outcomes. To fill this knowledge gap, we performed thorough structure/function, mechanistic, safety, and efficacy studies to assess the potential for AgNPs to treat TNBC. We establish that AgNPs, regardless of size, shape, or stabilizing agent, are highly cytotoxic to TNBC cells at doses that are not cytotoxic to non‐malignant breast epithelial cells. In contrast, TNBC cells and non‐malignant breast epithelial cells are similarly sensitive to exposure to silver cation (Ag(+)), indicating that the nanoparticle formulation is essential for the TNBC‐specific cytotoxicity. Mechanistically, AgNPs are internalized by both TNBC and non‐malignant breast cells, but are rapidly degraded only in TNBC cells. Exposure to AgNPs depletes cellular antioxidants and causes endoplasmic reticulum stress in TNBC cells without causing similar damage in non‐malignant breast epithelial cells. AgNPs also cause extensive DNA damage in 3D TNBC tumor nodules in vitro, but do not disrupt the normal architecture of breast acini in 3D cell culture, nor cause DNA damage or induce apoptosis in these structures. Lastly, we show that systemically administered AgNPs are effective at non‐toxic doses for reducing the growth of TNBC tumor xenografts in mice. This work provides a rationale for development of AgNPs as a safe and specific TNBC treatment. John Wiley and Sons Inc. 2019-09-30 /pmc/articles/PMC6996381/ /pubmed/32123812 http://dx.doi.org/10.1096/fba.2019-00021 Text en © 2019 The Authors. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Swanner, Jessica
Fahrenholtz, Cale D.
Tenvooren, Iliana
Bernish, Brian W.
Sears, James J.
Hooker, Allison
Furdui, Cristina M.
Alli, Elizabeth
Li, Wencheng
Donati, George L.
Cook, Katherine L.
Vidi, Pierre‐Alexandre
Singh, Ravi
Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
title Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
title_full Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
title_fullStr Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
title_full_unstemmed Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
title_short Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
title_sort silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996381/
https://www.ncbi.nlm.nih.gov/pubmed/32123812
http://dx.doi.org/10.1096/fba.2019-00021
work_keys_str_mv AT swannerjessica silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT fahrenholtzcaled silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT tenvooreniliana silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT bernishbrianw silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT searsjamesj silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT hookerallison silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT furduicristinam silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT allielizabeth silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT liwencheng silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT donatigeorgel silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT cookkatherinel silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT vidipierrealexandre silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo
AT singhravi silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo